Denosumab
From Ganfyd
rINN: Denosumab
Other Names
Xgeva®
Pharmacological Information
Web information on Denosumab
Relevant Clinical Literature
UK Guidance
Regulatory Literature
Other Literature
Please read pharmacological data limitations
Other Wikis
Medpedia on Denosumab (Less technical, good quality control)
Wikipedia on Denosumab (Less technical, ? quality control)
Denosumab is a synthetic human IgG2 monoclonal antibody. Its therapeutic target is a receptor required for survival and activity of osteoclasts called receptor activator of nuclear factor-κB ligand (RANKL). The presumed mechanism of action of denosumab is that blockage of the receptor reduces osteoclast-mediated bone resorption, thereby maintain bone mineral density[1]. It has been shown to be effective in reducing all major types of osteoporotic fractures in women[2] and in men receiving androgen-deprivation therapy for prostate cancer[3].
Contents |
Indications
- Osteoporosis
- Prevention of skeletal-related events in adults with bone metastases from solid tumours
Therapy
s/c twice yearly (osteoporosis).
Issues
Unclear if long term therapy could be associated with undesired immune modulation (eg eczema and cellulitis seem to be increased)
References
- ↑ Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006 Feb 23;354(8):821-31
- ↑ Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England journal of medicine. 2009 Aug 20; 361(8):756-65.(Link to article – subscription may be required.)
- ↑ Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. The New England journal of medicine. 2009 Aug 20; 361(8):745-55.(Link to article – subscription may be required.)
